Furthermore, it has been found that METTL14 can inhibit aerobic glycolysis in p53-wild-type colorectal cancer cells by suppressing the expression of SLC2A3 and PGAM1 in an m6A-dependent manner [22]. Here, METTL14 is linked to colorectal cancer.